Observational studyEuropean journal of drug metabolism and pharmacokinetics2026
Evaluation of Predictive Pharmacokinetic Models to Optimize Infliximab Therapy in Pediatric Inflammatory Bowel Disease.
Observational study in European journal of drug metabolism and pharmacokinetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe incidence of pediatric inflammatory bowel disease (IBD) rises yearly. Infliximab, a cornerstone of treatment, often has limited efficacy owing to high pharmacokinetic variability. Therapeutic drug monitoring and model-based precision dosing (MIPD) can improve optimal drug exposure.
objectiveThis study aimed to evaluate the predictive performance of available pediatric infliximab population pharmacokinetic (popPK) models implemented in specialized software during the induction phase of IBD treatment.
methodsThis retrospective observational cohort study included patients from January 2021 to December 2024. Plasma trough concentrations of infliximab were measured using an enzyme immunoassay. Pharmacokinetic simulations were performed with TDMx software, applying eight different pediatric popPK models. Metrics used to evaluate predictive performance included root mean squared error (RMSE), mean squared error (MSE), mean absolute error (MAE), mean absolute percentage error (MAPE), coefficient of determination, and relative bias.
resultsA total of 29 patients were included (Crohn's disease, n = 24; ulcerative colitis, n = 5; 52% female). Median (range) age was 12 (1-18) years and weight was 32 (7-62) kg. During the induction phase, patients received a median infliximab dose of 6.1 (4.6-10.2) mg/kg per infusion. The model by Dubinsky showed the best performance, including MSE, RMSE, MAE, and R CONCLUSIONS AND RELEVANCE: Pharmacotherapeutic assistance using MIPD software for infliximab precision dosing during induction in pediatric IBD is feasible and sufficiently accurate for clinical practice. In our population, the Dubinsky model was optimal for integration into dosing systems, balancing predictive performance with reliable PK representation.
Indexed as
Identifiers
41182539What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.